The RNA Pseudogene U7-102P: A Potential Drug Target and Biomarker

Target Name: RNU7-102P

NCBI ID: G106479064

RNU7-102P

Other Name(s): RNA, U7 small nuclear 102 pseudogene

The RNA Pseudogene U7-102P: A Potential Drug Target and Biomarker

Introduction

The RNA pseudogene U7-102P is a non-coding RNA molecule located within the U7 gene cluster on chromosome 7. U7 is a small nuclear RNA gene that is expressed in various tissues and organs, including brain, heart, and muscle. The U7 gene cluster contains several pseudogenes, including U7-101, U7-102, U7-103, and U7-104. Although all of these pseudogenes share a common start codon and a similar gene structure, they differ in their 3'-end. U7- 102P is the most well-studied pseudogene in the U7 gene cluster, and it is also the focus of ongoing research as a potential drug target and biomarker.

Structure and Expression

The U7-102P molecule is approximately 180 nucleotides long and has a single open reading frame (ORF) containing 12 exons. The ORF starts at nucleotide position +139 and includes the following consensus coding regions:

1. Promoter region: The U7-102P promoter region is located upstream of the start codon and consists of a series of GCC core promoter elements and a variable distance between the start codon and the first exon.
2. ORF1: The first exon in the U7-102P ORF is a stop codon, which terminates the RNA molecule at position +139.
3. ORF2: The second exon in the U7-102P ORF is a start codon, which introduces a new coding sequence starting at position +140.
4. ORF3: The third exon in the U7-102P ORF is a stop codon, which again terminates the RNA molecule at position +139.
5. ORF4: The fourth exon in the U7-102P ORF is an intron retention element (IRES), which is a unique feature of the U7 gene cluster. IRES elements are responsible for the retention of introns in exons and can be involved in the regulation of gene expression.
6. ORF5-7: The ORF5-7 regions in the U7-102P ORF encode a protein coding gene that is not highly conserved among different species.

RNA Expression and Biological Function

RNA expression is a critical process in the regulation of gene expression, and the U7-102P molecule is no exception. The U7-102P gene has been shown to be expressed in various tissues and organs, including brain, heart, and muscle. In addition , the U7-102P gene has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

RNA-based biomarkers are widely used in the diagnosis and prognosis of various diseases, including cancer. The U7-102P molecule has been shown to be involved in several cellular processes that are associated with the development and progression of cancer. For example, U7- 102P has been shown to be involved in the regulation of cell adhesion, which is a critical process for the maintenance of cancer cell stemness and the development of invasive tumors. In addition, U7-102P has been shown to play a role in the regulation of cell migration, which is critical for the development of cancer stem cells that can give rise to new tumors.

Drug Targeting

The U7-102P molecule is a potential drug target due to its unique structure and function. Several studies have shown that U7-102P can be inhibited by small molecules, leading to the relaxation of cell adhesion and the inhibition of cell migration. These results suggest that U7-102P could be a useful target for the development of anti-cancer drugs that inhibit cell adhesion and migration.

Conclusion

The U7-102P molecule is a non-coding RNA molecule located within the

Protein Name: RNA, U7 Small Nuclear 102 Pseudogene

The "RNU7-102P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU7-102P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets